Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

SciClone Buys China Rights to Anti-Nausea Drug

publication date: Jul 28, 2009

SciClone Pharmaceuticals has in-licensed China rights to Ondansetron RapidFilm, a product developed by APR Applied Pharma Research SA that uses thin-film technology to deliver an established nausea drug. The rapidly dissolving product is administered to treat side effects of nausea and vomiting following surgery, chemotherapy, and radiotherapy. More details...

Stock Symbol: (NSDQ: SCLN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital